Researchers from North Carolina State University have synthesized an analog of lipoxazolidinone A, a small molecule that is effective against drug-resistant bacteria such as MRSA. This molecule, a new synthetic compound inspired by a natural product, could be a useful chemical tool for studying other Gram-positive infections and may have implications for future drug creation.
Lipoxazolidinone A is a natural product which had been previously isolated from bacteria living in marine sediments. It is a secondary metabolite – a small molecule produced by the bacteria that isn’t key to its survival but is produced for a secondary purpose, like defense. When lipoxazolidinone A was initially isolated, researchers noted that it seemed effective against Gram-positive bacteria, like MRSA.
NC State chemist Joshua Pierce aimed to confirm those original findings and understand how the molecule’s structure correlated to its function; in short, he wanted to recreate the molecule to see what portions were directly responsible for its anti-microbial properties and then potentially improve upon that structure.
Pierce, along with current NC State graduate student Kaylib Robinson and former students Jonathan Mills and Troy Zehnder, used novel chemical tools to synthesize lipoxazolidinone A in the lab. They were able to confirm that its chemical structure matched what the initial researchers had indicated, then they worked to identify the portion of the molecule that was responsible for the activity against Gram-positive bacteria. Their result was a compound with improved potency, JJM-35.
They tested JJM-35 against a panel of resistant and non-resistant bacteria. When tested against MRSA in vitro, they found that the synthesized molecule was up to 50 times more effective than the natural product against several bacterial strains. Additionally, they found that the molecule was often more effective against resistant bacterial strains than it was against nonresistant strains.
“An exciting additional aspect of this work was that we identified that these molecules may function by inhibiting multiple biosynthetic pathways directly or indirectly,” says Pierce. “This means that bacteria may have difficulty developing resistance to potential drugs developed from these molecules.”
While more work is needed, Pierce hopes that JJM-35 and similar compounds can be used as tools to study other Gram-positive bacteria and provide a platform for the development of a novel class of anti-infective agents.
“At this point, we have a chemical scaffold – a starting piece of the puzzle. We know that this piece is effective, and so right now all efforts are focused on evaluating the properties of these molecules and their in vivo efficacy,” says Pierce. “The hope is that we can build upon this scaffold to create drugs that are effective against MRSA and other resistant bacteria at a time of dire need for antimicrobial development while also increasing the spectrum of activity.”
The Latest on: Antimicrobial development
via Google News
The Latest on: Antimicrobial development
- Program to Combat Threat of Antimicrobial Resistance Launchedon June 25, 2020 at 9:40 am
Antimicrobial resistance is a leading global health challenge that requires urgent action to ensure a safer world for everyone, everywhere ...
- Partnership to Fight Infectious Disease Launched to Address Antimicrobial Resistanceon June 25, 2020 at 9:01 am
The Partnership to Fight Chronic Disease (PFCD) today announced a new initiative to advance awareness on the growing problem of antimicrobial resistan ...
- Global Antimicrobial Coatings Market (2020 to 2025) - Drivers, Constraints and Challenges - ResearchAndMarkets.comon June 24, 2020 at 7:34 am
Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The global market for antimicrobial coatings was estimated to be $2,377.3 million in 2020. The antimicrobial ...
- New partnership aims to increase antimicrobial resistance data in 4 African nationson June 24, 2020 at 4:10 am
A new pilot program run by Pfizer, Wellcome, and the governments of Ghana, Kenya, Malawi, and Uganda aims to increase the surveillance of antimicrobial resistance. A lack of data on the scale of the ...
- Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africaon June 24, 2020 at 4:00 am
Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial ...
- Potentiation of Antibiotics by a Novel Antimicrobial Peptide against Shiga Toxin Producing E. coli O157:H7on June 22, 2020 at 2:11 am
Infection with Shiga toxin-producing Escherichia coli (STEC) results in hemorrhagic colitis and can lead to life-threatening sequelae including hemolytic uremic syndrome (HUS). Conventional treatment ...
- Global Antimicrobial Coatings for Medical Devices Market Analysis (2020 to 2026) - Featuring AST Products, BASF & Biointeractions Among Otherson June 17, 2020 at 1:27 pm
The "Global Antimicrobial Coatings For Medical Devices Market Analysis 2020" report has been added to ResearchAndMarkets.com's offering.
- Ascend Fast Tracks Antimicrobial Technology to Counter COVID-19 Shortageson June 16, 2020 at 2:10 pm
Acteev Protect combines zinc ion technology with polyamide-based woven, nonwoven, and knit fabrics to protect against microbial growth.
- meldCX and Kastus® announce next-generation antimicrobial touch screen partnershipon June 16, 2020 at 9:00 am
PRNewswire/ -- meldCX, an enterprise software solution provider that transforms the process of building and deploying apps for single-purpose ...
via Bing News